An exact method for link parameter estimation in error benchmarking: an application to Phase II two-stage single arm oncology trials

Barnes, Christopher N; Rai, Shesh N
October 2011
Statistical Methods in Medical Research;Oct2011, Vol. 20 Issue 5, p523
Academic Journal
Bayesian trial designs rely on the specification of a vague data prior to the determination of trial outcome. Phase II two-stage single arm oncology trials have a generally small sample size which may not provide the necessary amount of data to outweigh a misspecified or overly optimistic prior. To account for this issue, clinicians may wish to benchmark Bayesian errors with frequentist measures of trial validity, Type I and Type II errors. A confidence prior, reflecting the clinician’s confidence in the efficacy of the treatment before data accrual, is used to equate the errors across design strategies. An exact method, modelling both the inherent small sample size and multi-stage decision process of Phase II single arm trials, is presented for constructing the confidence prior.


Related Articles

  • THE CHOICE OF PHASE I BAYESIAN ADAPTIVE DESIGNS IN CHINA. H. PAN; Y. JI; Z. CHEN; C. LI; J. XIA // International Journal of Drug Discovery;2013, Vol. 5 Issue 1, p185 

    No abstract available.

  • Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lei, Xiudong; Yuan, Ying; Yin, Guosheng // Lifetime Data Analysis;Jan2011, Vol. 17 Issue 1, p156 

    In oncology, toxicity is typically observable shortly after a chemotherapy treatment, whereas efficacy, often characterized by tumor shrinkage, is observable after a relatively long period of time. In a phase II clinical trial design, we propose a Bayesian adaptive randomization procedure that...

  • New drug effective in the treatment of plaque psoriasis.  // Nursing Standard;6/4/2008, Vol. 22 Issue 39, p16 

    The article reports that ISA247, an alternative to ciclosporin, is safe and effective in the treatment of moderate to severe plaque psoriasis. ISA247 differs from ciclosporin with the result that its metabolites are excreted faster and there is a lower drug and metabolite load. Researchers in...

  • Bayesian dynamic models for survival data with a cure fraction. Sungduk Kim; Ming-Hui Chen; Dipak Dey; Dani Gamerman // Lifetime Data Analysis;Mar2007, Vol. 13 Issue 1, p17 

    Abstract??In this paper, we propose a new class of semi-parametric cure rate models. Specifically, we construct dynamic models for piecewise hazard functions over a finite partition of the time axis. Allowing the size of partition and the levels of baseline hazard to be random, our proposed...

  • Clinical trials and statistical verdicts: probable grounds for appeal. Diamond, George A.; Forrester, James S.; Diamond, G A; Forrester, J S // Annals of Internal Medicine;Mar83, Vol. 98 Issue 3, p385 

    Conventional interpretation of clinical trials relies heavily on the classic p value. The p value, however, represents only a false-positive rate, and does not tell the probability that the investigator's hypothesis is correct, given his observations. This more relevant posterior probability can...

  • The Pulse on Study Startup. Morgan, Craig // CenterWatch Weekly;1/9/2017, Vol. 21 Issue 1, p6 

    The article discusses use of basic metrics that helps to measure and improve clinical trial performances and reports bench-marking of trial data helps to run trials externally, resource allocation, and forecast future outcomes.

  • The volatility-confined LPPL model: A consistent model of ‘explosive’ financial bubbles with mean-reverting residuals. Lin, L.; Ren, R.E.; Sornette, D. // International Review of Financial Analysis;May2014, Vol. 33, p210 

    Abstract: Using the concept of the stochastic discount factor with critical behavior, we present a self-consistent model for explosive financial bubbles, which combines a mean-reverting volatility process and a stochastic conditional return which reflects nonlinear positive feedbacks and...

  • The impact of baseline faecal egg counts on the efficacy of single-dose albendazole against Trichuris trichiura Levecke, B.; Mekonnen, Z.; Albonico, M.; Vercruysse, J. // Transactions of the Royal Society of Tropical Medicine & Hygiene;Feb2012, Vol. 106 Issue 2, p128 

    Abstract: There is considerable variation in the efficacy of single-dose albendazole (400mg) against Trichuris trichiura across human trials. Factors contributing to this variation have not yet been identified. We assessed the impact of mean baseline faecal egg counts (FEC) on the efficacy of...

  • Review: Aspirin reduces vascular events but increases bleeding in primary and secondary prevention. Mukherjee, Debabrata; Baigent, C. // ACP Journal Club;9/22/2009, Vol. 151 Issue 3, p2 

    The article presents the findings of a study regarding the benefits and risks of aspirin. Aspirin is stated to reduce vascular events but increases bleeding in primary and secondary prevention. Primary prevention trials included patients who did not have diabetes and were scheduled for 2 years...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics